Peg Zuvigrast
Peg Filgrastim Injection
Strength
✓6 mg
Pack Size
1 Vial
Drug Class
Hematopoietic Growth Factors
Specification
USP/BP/IH Specs offered for exports
Storage
Store refrigerated at 2°C to 8°C.
Pegfilgrastim is a covalent conjugate of recombinant methionyl human GCSF (filgrastim) and monomethoxypolyethylene glycol.
Filgrastim is a water-soluble 175 amino acid protein with a molecular weight of approximately 19 kilodaltons.
Filgrastim is obtained from the bacterial fermentation of a strain of Escherichia coli transformed with a genetically engineered plasmid containing the human GCSF gene.
To produce pegfilgrastim, a 20 kDa monomethoxypolyethylene glycol molecule is covalently bound to the N-terminal methionyl residue of filgrastim.
The average molecular weight of pegfilgrastim is approximately 39 kDa.
Each syringe contains 6 mg Pegfilgrastim (based on protein weight) in a sterile, clear, colorless, preservative-free solution.
The pH of the solution is 4.0.
Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
Administration of pegfilgrastim is effective and safe in reducing the risk of grades 3/4 neutropenia and FN in breast cancer patients after receiving chemotherapy.
Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
- Read the label carefully before use.
- Keep out of the reach of children.
- Do not exceed the recommended dose.
The recommended dosage of pegfilgrastim is a single subcutaneous injection of 6 mg administered by subcutaneous route once per chemotherapy cycle.
Pegfilgrastim should not be administered in the period between 14 days before and 24 hours after administration of cytotoxic chemotherapy.
The 6 mg fixed-dose formulation should not be used in infants, children, and smaller adolescents weighing less than 45 kg.
No dosing adjustment is necessary for renal dysfunction.
Pegfilgrastim should be visually inspected for discolouration and particulate matter, and if found, should not be administered.